fbpx

Clinical Trial – Veterinarians CBD Knowledge

Updated: 6 months ago

Share on facebook
Share on twitter
Share on linkedin

Us Veterinarians Knowledge, Experience, and Perceptions Regarding the Use of Cannabidiol for Canine Medical Conditions. Published Jan 2019

1 – 2130 participants completed an anonymous online survey. It was created in collaboration with VIN (Veterinary Information Network-an online veterinary community). To evaluate views regarding marijuana and CBD/hemp products.

2 – Any participant who was not in clinical practice (n=26) or did not treat dogs (n=52) were eliminated from the survey.

3 – Participants were asked how often did their clients enquired about CBD products. Totals: rarely (29.2%) monthly (26.4%) never (8%) and daily (7.4%). Clients visiting veterinarians who worked in states that have legalized recreational marijuana were more likely to ask about CBD for their pet as noted in Table 2 chart in the trial.

4 – Participants were asked to identify the specific conditions or diseases for which clients were seeking information. More than one response was allowed. The 4 most common topics were for pain management, anxiety, seizures and storm/fireworks.

5 – Participants were asked about the endorsement of CBD products. Totals: never (44%) rarely (28.8%) sometimes (18.9%) frequently (8%). When asked what was the reason for not advising their clients only half answered the question. Totals: Not enough knowledge about CBD (68.1%) more research is needed (59.57%) it is illegal (48.8%) concerns about toxicity (19.7%)

6 – Perceived impact of CBD products for common canine medical conditions: Decrease’s pain for acute pain – somewhat helpful. Decrease’s pain for chronic pain – somewhat helpful. Reduces anxiety -somewhat helpful. Decrease’s seizures – somewhat helpful. Decrease’s pain for chronic pain – very helpful.

7 – Perception of state organizations’ provision of ‘sufficient guidance’ regarding the use of CBD. Strongly disagree (22%) Disagree (31%) Neutral (24%) Agree (17.3%) Strongly agree (4%)

8 – Overall all participants strongly agree that more toxicity research needs to be done.

9 – 83% Strongly disagree or disagree that CBD should remain a Schedule 1 drug as defined by the DEA. (CBD was removed from the Schedule 1 drug category in January 2020)

10 – 84% Strongly disagree or disagree that Hemp/CBD products for animals should remain illegal at the Federal level.

To view clinical trial: ncbi.nlm.nih.gov/pmc/articles/PMC6338022/

RELATED POSTS

Shopping Cart
Trust Guard Security Scanned

This website uses cookies to ensure you get the best experience on our website. By browsing this website, you agree to our use of cookies and verify you are at least 18 years of age.